April 09, 2020 04:00 PM Eastern Daylight Time ROCKVILLE, Md. & PROVIDENCE, R.I. & GOLDEN, Colo.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study ...
Immunomic Therapeutics Announces Completion of Pre-IND Meeting with US FDA for ITI-1001, a Vaccine for the Treatment of GBM
- Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM) - March 03, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held ...
Immunomic Therapeutics’ Collaborator, University of Florida Presents New Clinical Data from ATTAC-II Study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting
Nov. 20, 2019 ROCKVILLE, MD – Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD, ...
November 04, 2019 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that ...
Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM
- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) ...
Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. ...
July 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as ...
June 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. ...
Immunomic Therapeutics Announces Late-Breaking Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
February 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer ...
February 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animal ...
ITI Presents on Functional Evaluation of Isoforms Present in pDNA Vaccines at Aldevron’s Breakthrough Symposium
ITI's Michael Connolly, Manager of Process Development, presents a poster titled, "Functional evaluation of isoforms present in pDNA vaccines" at Aldevron's corporate offices located in Fargo, North Dakota A detailed abstract ...
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company presented at the 2018 BIO Investor Forum held in San Francisco, CA on October 17-18. William Hearl, Ph.D., Immunomic’s Founder ...